(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Description: 
To assess the safety and tolerability of MK-3475 (pembrolizumab) in HIVinfected patients on effective antiretroviral therapy and with relapsed/refractory or disseminated AIDS-defining or non-AIDS defining malignancy Hypothesis: MK-3475 (pembrolizumab) is safe and tolerable in patients with HIV and cancer who are on effective antiretroviral therapy.
Study Number: 

I 32316

Phase: 
1
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02595866

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.